Research programme: respiratory syncytial virus vaccine - AlphaVax

Drug Profile

Research programme: respiratory syncytial virus vaccine - AlphaVax

Alternative Names: RSV vaccine - AlphaVax; RSV-F vaccine - AlphaVax

Latest Information Update: 29 Oct 2013

Price : $50

At a glance

  • Originator AlphaVax
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 10 Nov 2012 Preclinical development is ongoing in USA
  • 01 Dec 2010 Preclinical trials in Respiratory syncytial virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top